sales@theinsightpartners.com
+1-646-491-9876 +44-20-8125-4005

Vectorized Antibodies For In Vivo Expression Market Scope And Analysis

  • Report Code : TIPRE00027649
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Analyse de la dynamique et de la portée du marché des anticorps vectorisés pour l'expression in vivo d'ici 2025-2031

Buy Now

Vectorized Antibodies for In Vivo Expression Market Report Vectorized Antibodies for In Vivo Expression Market Size and Share Vectorized Antibodies for In Vivo Expression Market Scope and Analysis

Vectorized Antibodies for In Vivo Expression Market Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) 13.4%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Technologie
  • vecteur de virus adéno-associé
  • électroporation
  • nanoparticules lipidiques
By Utilisateur final
  • institut de recherche
  • hôpitaux
  • autres
By Géographie
  • Amérique du Nord
  • Europe
  • Asie-Pacifique
  • Amérique du Sud et centrale
  • Moyen-Orient et Afrique
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • 4D Molecular Therapeutics (4DMT)
  • AbbVie
  • Adverum Biotechnologies
  • AstraZeneca
  • BioNTech
  • Curevac
  • Eli Lilly
  • Ethris
  • Eyevensys
    		•